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The h&xjynar+ effe&s of a new paretier@ for- 
mulation ,of nifedioine adminisiered by the intrave- 
nous (1. m$f) and @acoronary (ICZ) (0.1 and. O.? 
mg) route‘s tier? studied .In ‘30 patients with symp- 
tom&it5 ,aronary art&y disease undergoing c&&g- 
n&tic right- and M-sided cardiac catheterization. 
lntravetious nifedipine (I mg) reduced systemic 
vatiiar resistance by 34.% fp <O.O!), increased 
cardiac output by 28% (p <O.Ol) and de&ased 
mean arterial pressure by 10% (p <O.Oi). It had 
I&s eff&ct on peak positive dP/dl (-8% p 
<O.p25) and on peak yegative dP/dt (-15 % p 
<O.Oj). Coronary blood flow increased 20% (p 
50.025). in contrast, IC,nifedipine (0.2 mg) in- 
creased coronary blood flow 46% (p <0.025), 
depye+ed .contractitity as assessed by peak positive 
dP/dt (-26% b <O.Ol) and prolonged diastolic re- 
lax&ion tirire. The Meet of 0.1 mg was similar but 
iesq pronounced. These data suggest that the pri- 
mary therapeutic effect of nifedipine administered 
s$t&nicail* to.pritients tit rest results from an in- 
chase ih.cororjary blood flow and, to a lesser ex- 
tent, from afterload reduction; its myocardial de-, 
pri&sant effects are small, transient and masked by 
r&flex catecholamine release. IC nifdipine in- 
creas& coronary blood flciw, has a transient nega- 
iive @tropic effect and prolongs relajtation. The rel- 
ative limpdance of these myocardiai effects in 
preventing myocarbial ischemia is not known. 
(Am J Cardiol 1986;58:25-30) 
N ifedipine, a calcium-channel blocking drug, has 
negative inotropic and vasodilatory effects in vitro, but 
acts primarily as a vasodilator in vivo.*J It is effective 
in the treatment of angina pectoris dqe to coronary 
vasospasm3-5 or after exertion.6-8 Administered sys- 
temically, its efficacy in ameliorating pacing- and ex- 
ercise-induced angina ha.+ beeri attributed to afterload 
reductiorQJv9J’J to increased coronary blood flowgJl- 
via a direct vasodilatory effect or by reducing extrinsic 
cqronary vascular compressive forces in diastolesJOY 
and to a direct myocardial effeqt.lz Administered by 
the intracoronary (ICI route, nifedipine increases coro- 
nary sinus flow, *l-l3 decreases myocardial oxygen con- 
sumption,13J4 relieires spontaneous or ergonovine-in- 
duced coronary artery spasm4 and prolongs regional 
shortening,ls thereby prolongin’g relaxation time.16 
Kaitenbach et all2 observed that the antianginal effect 
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of IC nifedipine persisted for 10 minutes longer than 
its effect on hemodynamics and on coronary flow and, 
on that basis, suggested that intracoronary nifedipine 
has a direct myocardial effect. This study relates the 
direct myocardial effects of the drug administered by 
the IC route to changes in coronary blood flow in pa- 
tients with ischemic disease, and compares these ef- 
fects with those of nifedipine administered by the in- 
travenous [IV) route. 
blethdds 
Patierits: Ten patients (8 men, 2 women], 38 to 59 
years old, who underwent diagnostic cardiac catheter- 
iztitjon for symptomatic coronary artery disease were 
studied [Table I]. Mean ejection fraction was 63%. 
Nobe had valvular or congenital heart disease, unsta- 
ble angina, second- or third-degree heart block, major 
systemic disorders or diabetes mellitus. 
Protocol: Topical nitSate and P-blocker therapy 
were stopped 48 hours, and calcium-channel blocker 
therapy 72 hours before catheterization. After routine 
right- and left-sided cardiac catheterization and coro- 
nary arteriography, the baseline hemodynamic values 
were measured. They included heart rate, blood pres- 
sure, left ventricular pressure (4Fr or 5Fr Millar micro- 
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TABLE I Clinical Characteristics 
LV % Diameter Stenosis at CA 
Age WI EF W) 
Pt & Sex (%I (mm Hg) LM LAD LC R 
1 38M 71 126/20 . . . . . . 60 . . . 
2 63F 63 146/11 . . . . . 70 . . . 
3 63M 50 134712 50 . . . . . . . . 
4 59M 54 140/6 . . 40 . . . . . . 
5 55M 78 11419 . . . 60 . . . . . . 
6 49M 76 115/8 . . . 90 70 . . . 
7 46M 67 103/14 . . . . . . 90 . . . 
0 50M 55 106/6 . . 70 . . . 80 
9 50M 45 124111 . . . 90 . . . 90 
10 57M 68 107/12 . . . 50 . . . 90 
CA = coronary arteriography; EF = ejection fractfon; LAD = left anterior 
descending artet$ LC = left circumflex artery; LM = left main artery: LV (s/d) 
= left ventricular systoliclenddiastolic pressure; R = right coronary artery. 
manometer-tip catheter), electronically differentiated 
left ventricular dP/dt, pulmonary capillary wedge, 
pulmonary artery and right atria1 pressures, cardiac 
output (thermodilution, Swan-Ganz catheter) and cor- 
onary sinus flow (thermodilution, Wilton-Webster 
catheter through the left antecubital vein). Measure- 
ment of coronary blood flow remained stable: coro- 
nary flows measured before infusion of different 
doses were the same, and coronary flows at the end of 
a period of observation were the same as at the begin- 
ning (Tables 11, III and IV). After 2 successive mea- 
surements were stable, nifedipine (0.1 mg/lO ml of 
vehicle) was infused over 30 seconds with an infusion 
pump (Harvard model 28631 into the left coronary ar- 
tery. Pressures, cardiac output and coronary sinus flow 
were measured at baseline, after the infusion was 
stopped (time O] and at 1, 3; 5 and 10 minutes. After 
restabilization of tneasurements, 0.2 mg/lO ml of vehi- 
cle was infused over 60 seconds and measurements 
were repeated. Then, 1 mg was infused by the IV route 
over 3 minutes; measurements were made at the end of 
infusion, at 1,3,5 minutes and every 5 minutes thereaf- 
ter for 36 minutes. 
Evaluation of data: All phasic pressures were de- 
termined as the mean of 5 successive sinus beats over 1 
respiratory cycle. Cardiac outputs represent the mean 
of 3 measurements. The value of a~ hemodynamic pa- 
rameter was calculated as the absolute or percent dif- 
ference between the baseline value and each subse- 
quent value. The time constant of relaxation, 7, was 
derived from the best fit of a monoexponential to the 
time course of isovolumic left ventricular pressure de- 
cay.17J8 The correlation coefficients for these experi- 
mental fits were never less than 0.97. Statistical signifi- 
cance was determined using a Student t test on paired 
differences between the value of a hemodynamic vari- 
able at any time during the infusion and its baseline 
value. 
Results 
Systemic effects of nifedipine (Tables II, III and IV, 
Fig. 1 and 2): After IV administration, left ventricular 
systolic pressure decreased by 22 f 12 mm Hg [p 
<?.Ol), mean arterial pressure by 10 i 6 mm Hg (p 
<O.Oi) and systemic vascular resistance by 422 f 228 
dynes s cm+ (p <O.Ol). These effects lasted for only 5 
to 10 minutes. Heart rate increased transiently and 
cardiac index rose by 0.8 f 0.6 liters/min/m2 [p KO.01). 
As assessed by systolic pressure-rate product, external 
cardiac work was reduced for at least 15 minutes after 
drug administration. Left ventricular end-diastolic 
pressure, peak positive and negative dP/dt and 7 
hhanged little. In contrast, the systemic effects of IC 
nifedipine were h-d1 and short-lived. 
Direct effects of lriifedipine (Tables II, III and IV, 
Fig. 1 and 2): Cardiac: IC nifedipine (0.1 mg) depressed 
TABLE II Hemodynamic Effects of Inbacoronary Nifedlplne (a.1 mg) 
Time (minutes) 
Baseline 0 1 3 5 10 
PCW (mm Hg) 
LVEDP (mm Hg) 
+dP/dt (mm fig/s) 






MAP (mm Hg) 
LVSP (mm Hg) 
CO (litersimin) 
Cl (literslminlm*) 
SVR (dynes s cmm5) 
DP (% of baseline) 
7 f 219) +7 f l(2)+ +o.s * 2.563) +0.9 f 2.2(7) +I.0 f 2.0(8) +2.4 f 2.2(8)+ 
lOf5 +2f6 +1*5 0 f 4(9) +1*3 +1.4 zt 4 
1,067 f 171 -223 f 118’ -110 f 113+ -4f73 -4f73 
1,231 f 203 -366 f 216’ -221 f 83” -88 f 113(9) -72 f 126 -55 f 66 
45.0 f 6.9 +6.2 f 32 +4.2 i 20.0 +0.6 f 14.5 - +0.5 f 9.6 
162 f 27(6) +62 f 49(6)t +I6 i 22(2) +4 Y!C E(6) +2 f 26(6) 
0.56 f 0.14(6) -0.18 + 0.15(5) +0.06 f 0.1 i(6) +0.03 f 0.19(5) -0.01 f 0.15(5) 
73f 10 -l-7&7‘ +4f6 0 zt 6(9) Of6 +2f7 
94f 11 -11 i 415) -6 f 7(7) -1 f 7(7) -4 f 7(8) 0 & 14(9) 
122 f 15 -16 f 12’ -8& 13 -4 i S(9) +4f6+ +3fl2 
5.6 f 0.7 +0.4 f 0.4(6) +0.4 * 0.4(7)’ 0.2 -f 0.3(9) 0.3 f 0.5 
2.0 f 0.3 0.2 i 0.2(6) +0.3 f 0.2(7)’ -6.1 f 0.1(g)+ jo.2 f 0.2+ 
1,296 f 236 -201 f 253(5) -106 i 116(6) -33 f 124(9) -93 f 221 
109 99flO 100 zb 10 110f 15 
Data are expressed as the mean change from baseline ZL standard deviation. The number of patients evaluated is in parentheses unless the number is 10. 
l p <O.Ol; f p <0.025; t p <0.05 by paired t test. 
CBF = coronary blood flow; Cl = cardiac index: CO = cardiac output; CVR = coronary vascular resistance: DP = double product; +dP/dt = peak positive 
dP/dt; -dPldt = peak negative dP/dt; LVEDP = left ventricular end-diastolic pressure: LVSP = left ventricular systolic pressure; MAP = mean arterial pressure: 
PCW = pulmonary capillary wedge pressure; SVR = systemic vascular resistance; r = time constant of relaxation. 
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TABLE III Hemodynamic Effects of lniracoronary Nifedipine (0.2 mg) 
-- 
Time (minutes) 
















1,068 f 169 
1,169 f 164 
48.6 f 9.3 
172 i 30(6) 
0.51 f 0.12(6) 
71 f8 
92 f 9 
123 f 14 
5.8 f 0.5 
2.9 f 0.3 
1,197 f 169 
100 
+3 f 3(6) 
+6&4’ 
-273 f 116’ 
-327 f 173’ 
+13.1 f 8.0” 
+I1 f 8’ 
-6 f 3(5) 
-19 f 7” 
96.5 f 15.4 
-2 i 6(9) 
+3*3t 
-174 f 93’ 
-178 f 142’ 
+7.1 f IO.8(8) 
+79 f 71(6)t 
-0.16 f 0.12(6)7 
-+8fll 
-5 f il(9) 
-12 f 127 
+0.7 i 0.8(8)* 
0.2 f 0.4 
-130 f 165(9)t 
96.0 f 19.0 
Of3 
+1 f 4(9) 
-25 i 85(9) 
-113 f 292(9) 
-5.7 f 9.4(7) 
+1 f lO(4) 
-0.09 f 0.07(4) 
+2f7 
$1 f 12 
-267 
+0.5 f 1.0(4) 
+0.2 f 0.4(4) 
-91 f 186(4) 
Of2 0 f 2(8) 
fl zk2 -2 f 2(8)+ 
-2 k 48(10) -16 f 90(8) 
-7 zk 65(9) +32 f 87(8) 
-5.7 f 9.4(7) +0.2 f 7.9 
-9 f 37(6) -2 f 31(6) 
l-O.08 f 0.14(6) +0.05 f 0.1 l(6) 
-l&8 +1*7 
+6 3113 +4 f 15(8) 
-1 f8 +I f iO(8) 
0.0 f 0.7 +O.i f 0.7(8) 
+o.o * 0.5 +o.o f 0.4 
fll0 f 190 +48 i 159 
102 f 0 103 f 17 
Data are expressed as the mean change from baseline i standard deviation, The number of patients evaluated is in parentheses unless the number is 10. 
* p <O.Oi; t p <0.025; t p <0.05 by paired ttest. 
Abbreviations as in Table I. 
peak positive dP/dt by 223 f 118 mm Hg/s (p <O.Ol) 
and 0.2 mg of nifedipine by 273 f 116 mm Hg/s (p 
<O-01), significantly more than did IV nifedipine (87 f 
90 mm Hg/s p <0.025). These effects were transient. 
Nifedipine (0.2 mg IC] significantly depressed early 
diastolic relaxation: T was prolonged by 30% (p <O.Ol). 
It also reduced compliance, as reflected by the in- 
crease in left ventricular end-diastolic pressure. Al- 
though IV nifedipine significantly reduced peak nega- 
tive dP/dt, the effect was not significant, since T was 
unaffected. 
Coronary vascular: Both IV and IC nifedipine re- 
duced coronary vascular resistance by 30 to 40%. IC 
nifedipine, 0.1 mg, increased coronary blood flow by 
39 f 17% (p <0.05], and 0.2 mg by 46 f 17% (p <0.05] 
without altering myocardial oxygen consumption as 
assessed by the systolic pressure-rate product. IV ni- 
TABLE IV Hemodynamlc Effects of Intravenous Nlfediplne (1.0 mg) 
fedipine increased coronary blood flow by only 20%; 
nonetheless, this occurred without a significant reduc- 
tion in systolic pressure-rate product. 
Discussion 
Our data suggest that the antianginal effect of IV 
nifedipine results more from an increase in myocardi- 
al oxygen supply than from a reduction in myocardial 
oxygen consumption or in myocardial contractility. 
Despite the marked decrease in systemic vascular re- 
sistance, the reduction of mean arterial pressure was 
small. Reflex tachycardia, reflecting catecholamine 
release, precluded a marked and sustained reduction 
of systolic pressure-rate product, an adequate index of 
myocardial oxygen consumption that takes catechol- 
amine effects into account.lg KochzO observed higher 
catecholamine levels among patients undergoing su- 
Time (minutes) 














12 f 4 
1,081 f 203 
1,192 f 151 
48.3 f 10.8 
162 f 43(6) 
0.55 f O.ll(8) 
74 f 9 
94*7 
123 f 17 
5.9 f 0.9 
3.0 f 0.5 
1,238 f 262 
100 
1 f 2(8) 
+I&4 
-87 f 9Ot 
-172 f 131” 
+5.8 f 11.1 
+13 f 12’ 
-10 i 6(9)” 
-22 f 12” 
95 f: 8.8 
+I f 2(6) 
Of3 
-53 f 105 
-102 f 199 
+2.1 f 9.8(9) 
+34 f 26(6)t 
-0.17 f 0.05(5)’ 
+10 f 7t 
-13 f 5(8)* 
-21 f 12’ 
-i-1.7 f 1.1(9)” 
+0.8 f 0.6’ 
-422 f 228(8)* 
94 f 7 
+ 1.3 f 2.4(8) 
+1 f3 
+29 f 55 
-54 + 123 
+4.1 f 9.4(9) 
f23 f 23(5) 
-0.09 zk o.o7(5)t 
+6f8 
-8f6 
-14 f 13’ 
t 1.2 & 0.6(9)* 
0.6 f 0.3(9)* 
-327 f 161(8)* 
+lf2 Of2 Of2 
+113 +1*4 0 zk 3(9) 
-i-l8 f 97 -20 f 89 tll& 135 
-78 f 861 -52 f 79 -7 f 133(9) 
+4.1 f 9.4(9) $1.3 f 9.2 -4.3 f 10.8 
+27 f 55(6) +I2 f 19(6) +22 f 47(6) 
-0.02 f 0.15(6) -0.05 f 0.07(6) -0.05 * 0.08(8) 
+2f8 +I&6 -If8 
-4f7 -4f4 Of6 
-11 f 13’ -11 i 9’ +1 f 13 
+0.4 f 1.0(8)* 0.4 f 0.6t -0.2 f 1.0 
0.5 f 0.5(9)’ +0.2 i 0.3 -0.1 IO.4 
-270 f 229(g)+ -49 f 400 -12 rL: 188 
94f 10 92 f 9 103 & 14.6 
Data are expressed as the mean change from baseline f standard deviation. The number of patients evaluated is in parentheses unless the number is 10. 
* p <O.Ol; t p <0.025; t p <0.05 by paired t test. 
Abbreviations as in Table I. 
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pine bicycle exercise after administration of nifedi- 
pine than among control subjects. 
Our data are in agreement with those of Schanzen- 
bather et a1,13 who administered IV nifedipine to pa- 
tients at rest, and with those of Specchia et al? who 
reported that the antianginal potency of nifedipine ad- 
ministered systemically to patients with exercise-in- 
duced angina was attributable almost entirely to an 
increase in coronary blood flow. However, our data 
are at variance with other reports. Engel,g Emanuels- 
sonlo and their co-workers attributed the efficacy of 
nifedipine administered systemically to patients with 
pacing-induced angina both to afterload reduction and 
to increased myocardial perfusion. Moskowitz et al6 
found that systemic nifedipine ameliorated exercise- 
induced angina by reducing the double product at a 
given workload; however, myocardial oxygen supply 
was not measured. Kaltenbach et all2 reported that IV 
nifedipine reduced afterload and increased coronary 
n 0.2 mg ~c 
** 
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8 -20 - 
FIGURE 1. Peak hemodynamic effects of nifedipine infused by the 
intracoronary (IC) (0.2 mg) and intravenous (IV) (1.0 mg) routes. 
The difference between the baseline value and the peak value was 
calculated as a percentage of baseline value. The mean f standard 
error of the mean of the peak percentage change in all 10 patients is 
shown. +p <O.Ol; tp <0.025; l *p KO.05 by paired t test. CBF = 
coronary blood flow; CO = cardiac output; CVR = coronary vascu- 
lar resistance; +dP/dt = peak positive dP/dt; LVEDP = left ventric- 
ular end-diastolic pressure; MAP = mean arterial pressure; SVR = 
systemic vascular resistance; 7 = time constant of relaxation. 
blood flow, but also invoked a “direct myocardial in- 
fluence” to explain the drug’s antianginal effect. These 
differences may be explained by different doses and 
routes of drug administration, by the different levels of 
activity of the subjects or by different degrees of myo- 
cardial dysfunction. 
The direct myocardial and coronary vascular ef- 
fects of IC nifedipine help to rationalize the drug’s 
transient antianginal effect. IC nifedipine depressed 
contractility, as evidenced by the decrease in peak 
positive dP/dt, which occurred despite an increase in 
heart rate; this was not attributable to the decrease in 
mean arterial pressure, since a larger and more sus- 
tained decrease in arterial pressure after IV nifedipine 
was not accompanied by a reduction of peak positive 
dP/dt of a similar magnitude or durationz* This obser- 
vation is compatible with that of Serruys et a1,15 who 
noted prolongation of systolic shortening in the distri- 
bution of vein grafts after injection of nifedipine. Re- 
laxation was prolonged, as observed by Serruys,22 
Roussead6 and their co-workers, probably because of 
drug-induced asynchronous myocardial contraction16 
or to a direct myocardial effect on relaxation. Coro- 
nary blood flow was markedly increased in the ab- 
sence of a significant change in double product. Al- 
though these effects explain a short-term antianginal 
effect observed by others, 13,15 they do not explain the 
prolonged antianginal efficacy of IC nifedipine in ex- 
ercise-induced ischemia reported by Kaltenbach et 
a1.12 It is possible that autoregulatory mechanisms gov- 
erning coronary blood flow mobilized by pacing- or 
exercise-induced ischemia may potentiate the effects 
of nifedipine, or that a direct biochemical effect of the 
drug not studied explicitly may persist for up to 15 
minutes. 
Nifedipine has been reported to normalize relaxa- 
tions when it is prolonged by ischemia23-27; under non- 
ischemic conditions, it prolongs relaxation.16r22 IC ni- 
fedipine reduced peak negative dP/dt, although the 
effect may have been partially antagonized by cate- 
cholamine release.28p2g At the higher dose, T was signif- 
icantly prolonged; at the lower dose, the reduction of 
peak negative dP/dt was attributable to a fall in left 
ventricular peak systolic pressure.l7J8 Prolongation of 
diastole may reflect drug-induced slowing of calcium 
release in the perfused region, asynchronous contrac- 
tion and subsequent prolonged relaxation.16J2 Under 
the nonischemic and eucalcemic conditions of this 
study, it is less likely that nifedipine improves relaxa- 
tion by preventing intracellular calcium overload dur- 
ing systole, as suggested by recent studies of the effect 
of verapamil on chick embryo ventricular cells30 
The present study confirms that the use of a paren- 
teral formulation of nifedipine is safe, that IC nifedi- 
pine may be useful in the treatment of coronary spasm 
and that IV nifedipine may be useful in the treatment 
of hypertensive crises. In addition, the ability of IV 
nifedipine to lower systemic vascular resistance and 
increase cardiac output without depressing contractili- 
ty suggests that it may be useful in the treatment of 
cardiac failure, particularly cardiac failure due to cor- 
onary artery disease. 
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